(3R,4s)-1-氮杂双环[2.2.1]庚烷-3-羧酸 | 762208-37-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: (3R,4s)-1-氮杂双环[2.2.1]庚烷-3-羧酸
• 英文名称: 1-Azabicyclo[2.2.1]heptane-3-carboxylic acid
• CAS: 762208-37-7
• 化学式: C₇H₁₁NO₂
• 分子量: 141.17
• InChiKey: DJUYKFUHHWOHRZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.3
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Inhibitors of serine proteases, particularly HVC NS3-NS4A protease
  申请人：Cottrell M. Kevin

  公开号：US20050080017A1

  公开（公告）日：2005-04-14

  The present invention relates to compounds of formula I: or pharmaceutically acceptable salts thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.

  本发明涉及公式I的化合物或其药学上可接受的盐，其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒NS3-NS4A蛋白酶的活性。因此，它们通过干扰丙型肝炎病毒的生命周期而起作用，并且可用作抗病毒剂。本发明还涉及药学上可接受的组合物，包括上述化合物，用于体外使用或用于治疗患有HCV感染的患者的给药，以及制备该化合物的过程。本发明还涉及通过给予本发明中的化合物制备的药物组合物来治疗患有HCV感染的患者的方法。
• Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
  申请人：Cottrell M. Kevin

  公开号：US20050119189A1

  公开（公告）日：2005-06-02

  The present invention relates to compounds of formula I: or a pharmaceutically acceptable salts thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.

  本发明涉及式I的化合物：或其药学上可接受的盐，其抑制丝氨酸蛋白酶活性，特别是乙型肝炎病毒NS3-NS4A蛋白酶的活性。因此，它们通过干扰乙型肝炎病毒的生命周期而发挥作用，可用作抗病毒剂。本发明还涉及药学上可接受的组合物，包括上述化合物，用于体外使用或用于给患有HCV感染的患者使用，并涉及制备该化合物的方法。本发明还涉及通过给患者使用本发明的化合物制备的药物组合物治疗HCV感染的方法。
• INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE
  申请人：Cottrell Kevin M.

  公开号：US20080125376A1

  公开（公告）日：2008-05-29

  The present invention relates to compounds of formula I: or pharmaceutically acceptable salts thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.

  本发明涉及公式I的化合物：或其药学上可接受的盐，其抑制丝氨酸蛋白酶活性，特别是乙型肝炎病毒NS3-NS4A蛋白酶的活性。因此，它们通过干扰乙型肝炎病毒的生命周期来发挥作用，并且可用作抗病毒剂。本发明还涉及药学上可接受的组合物，包括上述化合物，用于体外使用或用于治疗患有HCV感染的患者的给药。本发明还涉及制备该化合物的方法。本发明还涉及通过给予本发明化合物的药物组合物治疗患有HCV感染的患者的方法。
• Novel bridged bicyclic N-heterocycles
  申请人：BEECHAM GROUP PLC

  公开号：EP0261763A1

  公开（公告）日：1988-03-30

  A compound of formula (I) or a pharmaceutically acceptable salt thereof: in which X represents a group in which p represents an integer of 2 to 4; r represents an integer of 1 or 2; s represents 0 or 1; and A represents a 3-membered divalent residue completing a 5-membered aromatic ring and comprises one or two heteroatoms selected from oxygen, nitrogen and sulphur, any amino nitrogen optionally substituted by a C 1-4 alkyl group, and when (p,r,s) is (2,2,0) or (2,2,1) any A comprising 2 heteroatoms is optionally C-substituted by a methyl group, and when (p,r,s) is (2,1,0), (2,1,1) or (3,1,0) any A comprising 2 heteroatoms is optionally C-substituted by C 1-2 alkyl and any A comprising one heteroatom is optionally C-substituted by a methyl group, and wherein compounds of formula (I) having two assymetric centres have the stereo-chemical configuration in which the group X and the (CH₂) r bridge are on the same side of the plane of the molecule which contains both bridgehead atoms and the ring carbon atom bonded to the group X.

  式 (I) 的化合物或其药学上可接受的盐： 其中 X 代表一个基团 其中 p 代表 2 至 4 的整数；r 代表 1 或 2 的整数；s 代表 0 或 1；以及 A 代表完成 5 元芳香环的 3 元二价残基，包含一个或两个选自氧、氮和硫的杂原子、当（p,r,s）为（2,2,0）或（2,2,1）时，包含 2 个杂原子的任何 A 可选择被一个甲基取代，当（p,r,s）为（2,1,0）、（2,1,1）或（3,1、0）时，包含 2 个杂原子的任何 A 可任选由 C 1-2 烷基取代，包含 1 个杂原子的任何 A 可任选由甲基取代，其中具有两个同义中心的式 (I) 化合物具有立体化学构型，其中基团 X 和 (CH₂) r 桥位于分子平面的同一侧，分子平面包含桥头原子和与基团 X 键合的环碳原子。
• Azabicyclic compounds, process and intermediates for their preparation and pharmaceutical compositions containing them
  申请人：BEECHAM GROUP PLC

  公开号：EP0257741A2

  公开（公告）日：1988-03-02

  A compound of formula (I) or a pharmaceutically acceptable salt thereof: in which A represents a bond or -CH₂- and B represents hydrogen, or A and B together with carbon atom to which they are both attached represents a group -CH=C ; R represents R₁OOC- in which R₁ is C1-4 alkyl, C2-4 alkenyl or C2-4 alkynyl; R₂O- in which R₂ is C1-3 alkyl, C1-2 alkylcarbonyl or aminocarbonyl optionally substituted by one or two methyl groups; or R₃CH₂⁻ in which R₃ is C1-2 alkoxy; and p represents an integer of 2 to 4, and wherein compounds of formula (I) where B is hydrogen have the stereochemical configuration in which the group R and the methylene bridge are both on the same side of the plane of the molecule which contains both bridge head atoms and the ring carbon atom bonded to the group R.

  一种式(I)化合物或其药学上可接受的盐： 其中 A 代表键或-CH₂-，B 代表氢，或 A 和 B 连同它们所连接的碳原子代表一个基团 -CH=C；R 代表 R₁OOC-，其中 R₁ 是 C1-4 烷基、C2-4 烯基或 C2-4 烷炔基；R₂O-，其中 R₂ 是 C1-3 烷基、C1-2 烷基羰基或可选被一个或两个甲基取代的氨基羰基；或 R₃CH₂-，其中 R₃ 是 C1-2 烷氧基；以及 p 代表 2 至 4 的整数，其中 B 是氢的式 (I) 化合物具有立体化学构型，其中基团 R 和亚甲基桥位于分子平面的同一侧，分子平面包含桥头原子和与基团 R 键合的环碳原子。